Wednesday , December 19 2018
Breaking News
Home / BUSINESS / USFDA conducts inspection at Biocon’s Bengaluru facility
USFDA conducts inspection at Biocon’s Bengaluru facility

USFDA conducts inspection at Biocon’s Bengaluru facility

United States Food and Drug Administration (USFDA) has conducted a pre-approval inspection of Biocon’s new Oral Solid Dosage Forms manufacturing facility at Bengaluru from November 05 to 09. The audit concluded without any observations and no Form 483 was issued.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.

Leave a Reply

Your email address will not be published. Required fields are marked *

*